Elevated Expression of Lipoprotein-Associated Phospholipase A2 in Calcific Aortic Valve Disease Implications for Valve Mineralization

被引:104
|
作者
Mahmut, Ablajan [1 ]
Boulanger, Marie-Chloe [1 ]
El Husseini, Diala [1 ]
Fournier, Dominique [1 ]
Bouchareb, Rihab [1 ]
Despres, Jean-Pierre [2 ]
Pibarot, Philippe [2 ]
Bosse, Yohan [2 ]
Mathieu, Patrick [1 ]
机构
[1] Univ Laval, Grp Rech Valvulopathies, Lab Etud Mol Valvulopathies, Quebec Heart & Lung Inst,Res Ctr,Dept Surg, Quebec City, PQ, Canada
[2] Inst Univ Cardiol & Pneumol Quebec, Quebec City, PQ G1V 4G5, Canada
关键词
apoptosis; calcific aortic valve disease; ectonucleotide pyrophosphatase/phosphodiesterase 1; lipoprotein-associated phospholipase A2; lysophosphatidylcholine; protein kinase A; valve interstitial cells; LOW-DENSITY-LIPOPROTEIN; LDL OXIDATION; A(2); INFLAMMATION; STENOSIS; ACETYLHYDROLASE; PYROPHOSPHATE; INHIBITION; PHOSPHATE; PLASMA;
D O I
10.1016/j.jacc.2013.05.105
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives This study sought to document the presence and role of lipoprotein-associated phospholipase A2 (Lp-PLA2) in calcific aortic valve disease (CAVD). Background CAVD is a chronic disorder characterized by pathological mineralization and remodeling. Studies have indicated that human CAVD tissues are infiltrated by lipids and that inflammation may play a role in the pathobiology. We hypothesized that Lp-PLA2 (encoded by the PLA2G7 gene) is expressed in CAVD and may play a role in the mineralization of valve interstitial cells. Methods We have documented the expression of the phospholipase A2 family of genes in aortic valves by using a transcriptomic assay. Messenger ribonucleic acid and protein expression were confirmed in aortic valves explanted from 60 patients by quantitative polymerase chain reaction and immunohistochemistry, respectively. The effect of lysophosphatidylcholine, the product of Lp-PLA2 activity, was documented on the mineralization of valve interstitial cell cultures. Results Transcriptomic analyses of CAVD and control nonmineralized aortic valves revealed that Lp-PLA2 was increased by 4.2-fold in mineralized aortic valves. Higher expression of Lp-PLA2 in stenotic aortic valves was confirmed by quantitative polymerase chain reaction, immunohistochemistry, and enzymatic Lp-PLA2 activity. The number of Lp-PLA2 transcripts correlated with several indexes of tissue remodeling. In vitro, lysophosphatidylcholine increased the expression of alkaline phosphatase, the ectonucleotide pyrophosphatase/phosphodiesterase 1 enzyme, sodium-dependent phosphate cotransporter 1 (encoded by the SLC20A1 gene), and osteopontin. We then showed that lysophosphatidylcholine-induced mineralization involved ectonucleotidase enzyme as well as apoptosis through a protein-kinase-A-dependent pathway. Conclusions Together, these results demonstrated that Lp-PLA2 is highly expressed in CAVD, and it plays a role in the mineralization of valve interstitial cells. Further work is necessary to document whether Lp-PLA2 could be considered as a novel target in CAVD. (C) 2014 by the American College of Cardiology Foundation
引用
收藏
页码:460 / 469
页数:10
相关论文
共 50 条
  • [1] Lipoprotein-associated phospholipase A2 activity, genetics and calcific aortic valve stenosis in humans
    Perrot, Nicolas
    Theriault, Sebastien
    Rigade, Sidwell
    Chen, Hao Yu
    Dina, Christian
    Martinsson, Andreas
    Boekholdt, S. Matthijs
    Capoulade, Romain
    Le Tourneau, Thierry
    Messika-Zeitoun, David
    Engert, James C.
    Wareham, Nicholas J.
    Clavel, Marie-Annick
    Pibarot, Philippe
    Smith, J. Gustav
    Schott, Jean Jacques
    Mathieu, Patrick
    Bosse, Yohan
    Thanassoulis, George
    Arsenault, Benoit J.
    HEART, 2020, 106 (18) : 1407 - 1412
  • [2] Lipoprotein-Associated Phospholipase A2 Activity, Genetics, and Risk of Calcific Aortic Valve Stenosis in Humans
    Perrot, Nicolas
    Theriault, Sebastien
    Pibarot, Philippe
    Clavel, Marie-Annick
    Mathieu, Patrick
    Bosse, Yohan
    Arsenault, Benoit
    CIRCULATION, 2018, 138
  • [3] Lipoprotein-associated phospholipase A2 is elevated in patients with severe aortic valve stenosis without clinically overt atherosclerosis
    Kolasa-Trela, Renata
    Fil, Korneliusz
    Bazanek, Marta
    Grudzien, Grzegorz
    Sobczyk, Dorota
    Sadowski, Jerzy
    Undas, Anetta
    CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2012, 50 (10) : 1825 - 1831
  • [4] New Therapeutic Targets for Calcific Aortic Valve Stenosis The Lipoprotein(a)-Lipoprotein-Associated Phospholipase A2-Oxidized Phospholipid Axis
    Hung, Ming-Yow
    Witztum, Joseph L.
    Tsimikas, Sotirios
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2014, 63 (05) : 478 - 480
  • [5] Elevated Lipoprotein-Associated Phospholipase A2 Is Associated With Intracranial Atherosclerosis
    Wang, Yuan
    Liu, Gang
    Song, Haiqing
    Cao, Catherine
    Ji, Xunming
    Cao, Guodong
    FRONTIERS IN NEUROLOGY, 2022, 13
  • [6] Lipoprotein-associated phospholipase A2
    McConnell, Joseph P.
    Hoefner, Daniel M.
    CLINICS IN LABORATORY MEDICINE, 2006, 26 (03) : 679 - +
  • [7] Lipoprotein-associated phospholipase A2 levels are elevated in obese children
    Sakka, S.
    Kaminioti, C.
    Pervanidou, P.
    Lazopoulou, N.
    Kanaka-Gantenbein, C.
    Chrousos, G.
    Papassotiriou, I.
    CLINICAL BIOCHEMISTRY, 2011, 44 (07) : 539 - 539
  • [8] Risk of stroke and elevated levels of lipoprotein-associated phospholipase A2
    Alberts, Mark J.
    Ballantyne, Christie
    Elkind, Mitchell S.
    STROKE, 2008, 39 (02) : 642 - 642
  • [9] Lipoprotein-associated Phospholipase A2 in Coronary Artery Disease
    Dimitroglou, Yannis
    Sakalidis, Athanasios
    Mavroudis, Andreas
    Kalantzis, Charalambos
    Valatsou, Angeliki
    Andrikou, Ioannis
    Christofi, Angela
    Mantzouranis, Emmanouil
    Kachrimanidis, Ioannis
    Bei, Evellina
    Lazarou, Emilia
    Tsioufis, Costas
    Tousoulis, Dimitris
    Lazaros, George
    CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2022, 22 (28) : 2344 - 2354
  • [10] Lipoprotein-associated Phospholipase A2 and Coronary Heart Disease
    Sofogianni, Areti
    Alkagiet, Stelina
    Tziomalos, Konstantinos
    CURRENT PHARMACEUTICAL DESIGN, 2018, 24 (03) : 291 - 296